Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ultragenyx Pharmaceutical (RARE) Return on Sales (2017 - 2025)

Historic Return on Sales for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Q3 2025 value amounting to 1.13%.

  • Ultragenyx Pharmaceutical's Return on Sales fell 1700.0% to 1.13% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.92%, marking a year-over-year increase of 1500.0%. This contributed to the annual value of 1.02% for FY2024, which is 3800.0% up from last year.
  • Per Ultragenyx Pharmaceutical's latest filing, its Return on Sales stood at 1.13% for Q3 2025, which was down 1700.0% from 0.69% recorded in Q2 2025.
  • In the past 5 years, Ultragenyx Pharmaceutical's Return on Sales ranged from a high of 0.69% in Q2 2025 and a low of 2.7% during Q3 2022
  • Moreover, its 5-year median value for Return on Sales was 1.41% (2021), whereas its average is 1.36%.
  • Over the last 5 years, Ultragenyx Pharmaceutical's Return on Sales had its largest YoY gain of 19100bps in 2021, and its largest YoY loss of -18200bps in 2021.
  • Ultragenyx Pharmaceutical's Return on Sales (Quarter) stood at 1.5% in 2021, then dropped by 0bps to 1.5% in 2022, then surged by 36bps to 0.97% in 2023, then grew by 15bps to 0.82% in 2024, then plummeted by -38bps to 1.13% in 2025.
  • Its Return on Sales was 1.13% in Q3 2025, compared to 0.69% in Q2 2025 and 1.08% in Q1 2025.